P J Spiess
Overview
Explore the profile of P J Spiess including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1287
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rosenberg S, Yang J, Schwartzentruber D, Hwu P, Marincola F, Topalian S, et al.
J Immunol
. 1999 Jul;
163(3):1690-5.
PMID: 10415076
Patients with metastatic melanoma were immunized with an immunodominant peptide derived from the gp100 melanoma-melanocyte differentiation Ag that was modified to increase binding to HLA-A+0201. A total of 10 of...
2.
Clay T, Custer M, Spiess P, Nishimura M
Pathol Oncol Res
. 1999 Mar;
5(1):3-15.
PMID: 10079371
The purpose of this review is to illustrate some of the technical and biological hurdles that need to be addressed when developing new gene therapy based clinical trials. Gene transfer...
3.
Rosenberg S, Yang J, Schwartzentruber D, Hwu P, Marincola F, Topalian S, et al.
Nat Med
. 1998 Mar;
4(3):321-7.
PMID: 9500606
The cloning of the genes encoding cancer antigens has opened new possibilities for the treatment of patients with cancer. In this study, immunodominant peptides from the gp100 melanoma-associated antigen were...
4.
McCabe B, Irvine K, Nishimura M, Yang J, Spiess P, Shulman E, et al.
Cancer Res
. 1995 Apr;
55(8):1741-7.
PMID: 7536130
Anticancer vaccine strategies can now target intracellular antigens that are involved in the process of malignant transformation, such as oncogene products or mutated tumor suppressor genes. Fragments of these antigens,...
5.
Minev B, McFarland B, Spiess P, Rosenberg S, Restifo N
Cancer Res
. 1994 Aug;
54(15):4155-61.
PMID: 7518351
CD8+ T-lymphocytes (TCD8+) recognize minimal peptides of 8-10 residues which are the products of intracellularly processed proteins and are presented at the cell surface by major histocompatibility complex class I...
6.
Restifo N, Spiess P, Karp S, Mule J, Rosenberg S
J Exp Med
. 1992 Jun;
175(6):1423-31.
PMID: 1588273
To be recognized by CD8+ T lymphocytes, target cells must process and present peptide antigens in the context of major histocompatibility complex (MHC) class I molecules. The nonimmunogenic, low class...
7.
Barth Jr R, Mule J, Spiess P, Rosenberg S
J Exp Med
. 1991 Mar;
173(3):647-58.
PMID: 1900079
We have investigated the mechanisms whereby adoptively transferred murine CD8+ lymphocytes mediate tumor regressions. Noncytolytic, CD8+ tumor-infiltrating lymphocytes (TIL) eradicated established lung tumors in irradiated mice. Many cytolytic and noncytolytic...
8.
Fox B, Spiess P, Kasid A, Puri R, Mule J, Weber J, et al.
J Biol Response Mod
. 1990 Oct;
9(5):499-511.
PMID: 2174966
We have shown that a T-cell clone derived from murine tumor-infiltrating lymphocytes (TILs) can be established that mediates in vitro and in vivo antitumor effects. Utilizing this clone as a...
9.
Cameron R, Spiess P, Rosenberg S
J Exp Med
. 1990 Jan;
171(1):249-63.
PMID: 2295878
The adoptive transfer of tumor-infiltrating lymphocytes (TIL) with the concomitant administration of IL-2 has been shown to mediate the regression of established 6- and 14-d murine hepatic and pulmonary metastases....
10.
Rosenberg S, Schwarz S, Spiess P
J Natl Cancer Inst
. 1988 Nov;
80(17):1393-7.
PMID: 3262772
Attempts have been made to design optimal strategies for the immunotherapy of established tumors. In mice bearing pulmonary metastases from sarcomas, a substantial therapeutic synergy was seen when both interleukin-2...